The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches

Cell division cycle 25B is a key cell cycle regulator and widely considered as potent clinical drug target for cancers. This research focused on identifying potential compounds in theory which are able to disrupt transient interactions between CDC25B and its CDK2/Cyclin A substrate. By using the met...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hong-Lian, Ma, Ying, Li, Yu, Chen, Xiu-Bo, Dong, Wei-Li, Wang, Run-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464863/
https://www.ncbi.nlm.nih.gov/pubmed/28402259
http://dx.doi.org/10.18632/oncotarget.16600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464863/
https://www.ncbi.nlm.nih.gov/pubmed/28402259
http://dx.doi.org/10.18632/oncotarget.16600

Ejemplares similares